Eli Lilly unveils TuneLab, an AI-driven drug discovery platform backed by a $1 billion research investment, offering biotech companies access to AI models built on Lilly's extensive drug data and joining Lilly Catalyze360's offerings for biotech partners.
MIT researchers unveil VaxSeer, an AI tool that accurately predicts dominant flu strains and optimizes vaccine design months ahead, outperforming WHO selections in a 10-year study by simulating virus evolution and vaccine responses using deep learning models.
Researchers harness AI to uncover abaucin, a groundbreaking antibiotic disrupting lipoprotein trafficking, offering a potent weapon against drug-resistant Acinetobacter baumannii bacteria, sparking hope for treating stubborn wound infections.
Generative AI pioneers novel antibiotics that disrupt bacterial cell membranes, offering potential solutions against drug-resistant gonorrhea, MRSA, and other superbugs in the ongoing battle against antimicrobial resistance.
Groundbreaking AI models generate novel antibiotics NG1 and DN1 that effectively combat multidrug-resistant superbugs like gonorrhea and MRSA, iteratively building and optimizing molecular structures for potency and safety.
AI startup Isomorphic Labs, spun out of DeepMind, prepares for human trials of drugs designed by cutting-edge AI paired with pharma experts, aiming for 100% conviction drugs will work before trials, promising faster, cheaper and more accurate medicine design.
AI's ability to rapidly analyze massive datasets is revolutionizing drug discovery, cutting research timelines from around 6 years to as little as 2-4 years, leading to significant cost savings and faster delivery of life-saving treatments, as evidenced by the accelerated development of COVID-19 mRNA vaccines.
OpenAI is in discussions with the FDA to explore leveraging AI, potentially through a project called cderGPT, to accelerate the drug approval process, with the FDA commissioner confirming the agency's first AI-assisted scientific review of a product.
Researchers developed a machine-learning model that can predict the transition states of chemical reactions in under a second with high accuracy, enabling efficient design of useful compounds like fuels and drugs by rapidly exploring potential reaction pathways.
Tempus AI unveils groundbreaking $200M deals with AstraZeneca and Pathos AI to build the largest AI model in oncology, harnessing multimodal data to drive biological insights, drug target discovery, and therapeutic development for cancer patients.